To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
About This Bill
Committee
Latest Action · November 10, 2023
Referred to the Subcommittee on Innovation, Data, and Commerce.